Eric Schlumpf News Today

A clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment ey

Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today an

Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today an

/PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical...

STUART, Fla., Dec. 29, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical stage biopharmaceutical company conducting research and development of unique extracellular matrix-targeting peptide therapeutics for ophthalmic diseases, today

/PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical stage biopharmaceutical company conducting research and development of unique extracellular...

Stuart Therapeutics, Inc. ("Stuart"), a clinical stage biopharmaceutical company conducting research and development of unique extracellular matrix-targeting peptide therapeutics for ophthalmic diseases, today announced the First Patient First Visit...

/PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart") today announced that it has entered into a license agreement with Glaukos Corporation ("Glaukos") under...

Stuart Therapeutics, Inc. ("Stuart") today announced that it has entered into a license agreement with Glaukos Corporation ("Glaukos") under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart's proprietary...

STUART, Fla., Jan. 3, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc., (hereinafter Stuart) announces that it has entered into a license agreement ...